Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690122 | 0.82 | KAT2B (0.56) | MEN1KMT2AKAT2BMAPTNPC1 | |
| SCHEMBL5550215 | 0.81 | KAT2B (0.55) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL737318 | 0.79 | MEN1 (0.62) | MEN1KMT2AKAT2BMAPTRAB9A | |
| SCHEMBL8871936 | 0.77 | MEN1 (0.52) | MEN1KMT2AHTR6MAPTRAB9A | |
| SCHEMBL21751695 | 0.77 | MAPT (0.59) | MEN1KMT2AMAPTSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL21751590 | 0.76 | MAPT (0.58) | MEN1KMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL21331195 | 0.75 | KAT2B (0.57) | MEN1KMT2AKAT2BMAPTNPC1 | |
| SCHEMBL14960166 | 0.74 | KAT2B (0.53) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11712746 | 0.74 | KAT2B (0.59) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11715381 | 0.73 | HTT (0.60) | KMT2AKAT2BHTR6MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | MEN1 2181/4885KMT2A 675/4885KAT2B 1403/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | MEN1 2181/4885KMT2A 675/4885KAT2B 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.